2 months ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? Zacks
ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
X